Rajeev Singh, MD
Cardiovascular Disease · Atlanta, GANPI 1194169417
Payments from drug & device makers
Across 456 payments — averaging $34.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Novartis$2K
- Cvrx, Inc.$834
- Alnylam Pharmaceuticals Inc.$790
- Merck$748
- AstraZeneca$710
- plus $4K from 30 others
What the payments were for
- Consulting fees$5,00032%
- Travel & lodging$3222%
- Food & beverage$10,24065%
- Education$1951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $7,292 |
| Novartis | 95 | $1,522 |
| Cvrx, Inc. | 25 | $834 |
| Alnylam Pharmaceuticals Inc. | 38 | $790 |
| Merck | 40 | $748 |
| AstraZeneca | 34 | $710 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $673 |
| E.r. Squibb & Sons, L.L.C. | 39 | $666 |
| Boehringer Ingelheim | 29 | $586 |
| Bridgebio Pharma, Inc. | 16 | $252 |
| Medtronic | 5 | $221 |
| Pfizer | 10 | $202 |
| Penumbra, Inc. | 1 | $161 |
| Boston Scientific | 5 | $140 |
| Picard Medical Inc. | 1 | $109 |
| Bayer | 4 | $104 |
| Impulse Dynamics (USA) Inc. | 3 | $68 |
| Scpharmaceuticals Inc. | 2 | $67 |
| Novo Nordisk | 3 | $63 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Kestra Medical Technology Services, Inc. | 3 | $56 |
| Eurofins Viracor, LLC | 1 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $48 |
| Johnson & Johnson | 3 | $46 |
| Amgen | 2 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| La Jolla Pharmaceutical Company | 2 | $30 |
| Edwards Lifesciences | 1 | $27 |
| Sanofi | 1 | $22 |
| Atricure, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Abiomed | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Argon Medical Devices, Inc. | 1 | $16 |
| Nuwellis, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,757 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 50 | $1,142,013 |
| EntrestoSacubitril/Valsartan | 428 | $487,167 |
| CamzyosMavacamten | 32 | $260,262 |
| JardianceEmpagliflozin | 176 | $218,996 |
| FarxigaDapagliflozin Propanediol | 191 | $202,103 |
| EliquisApixaban | 129 | $137,450 |
| XareltoRivaroxaban | 16 | $17,763 |
| VerquvoVericiguat | 19 | $12,148 |
| Tacrolimus | 26 | $9,342 |
| Torsemide | 287 | $4,307 |
| Metoprolol Succinate | 285 | $3,295 |
| Midodrine Hcl | 16 | $2,979 |
| Spironolactone | 361 | $2,636 |
| Mycophenolate Mofetil | 19 | $2,483 |
| Eplerenone | 34 | $1,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $202 | $1,279,463179 claims |
| NovartisEntresto | $1,522 | $487,167428 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $666 | $260,26232 claims |
| Boehringer IngelheimJardiance | $586 | $218,996176 claims |
| AstraZenecaFarxiga | $710 | $202,103191 claims |
| Johnson & JohnsonXarelto | $46 | $17,76316 claims |
| MerckVerquvo | $748 | $12,14819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Bobby KhanAtlanta$1.7M
- Michael MorrisAtlanta$1.1M
- Modele OgunniyiAtlanta$1M
- Joseph MillerAtlanta$771K
- Mani VannanAtlanta$716K
- Gautam KumarAtlanta$639K
- Melvin EcholsAtlanta$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.